IDEXX Laboratories, Inc. (IDXX) 2024 10-K Earnings Analysis
IDEXX Laboratories, Inc.2024 Earnings Analysis
80/100
IDEXX Laboratories, Inc.'s 10-K for the period ended December 31, 2024 shows a company with real operating weight: $3.90B of revenue, $888M of net income, and $808M of free cash flow. Catalyst In-Clinic Analyzer, ProCyte / SediVue, and In-Clinic Instrument Base remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Margins held at 61.0% gross and 29.0% operating, and that is easier to believe once you look at Catalyst In-Clinic Analyzer. The real follow-up question is whether the present return profile survives the next change in demand or mix. The filing itself uses a phrase worth keeping: 'and all subsidiaries that are consolidated under U.S'.
Filing analysis
IDEXX Laboratories, Inc. 2024 10-K Analysis
This page reads IDEXX Laboratories, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 80/100, or grade B.
IDXX Earnings Quality
The earnings-quality module scores 83/100, with Gross Margin: 61.0%, Operating Margin: 29.0%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
IDXX Economic Moat Analysis
The moat-strength module scores 87/100, with In-Clinic Instrument Base: Razor/blades model, Reference Lab Network: Global footprint. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
IDXX Free Cash Flow vs Net Income
CF/Net Income: 1.05x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
IDXX Key Risks from the Annual Report
The risk module scores 73/100, with Vet Clinic Visit Volumes: Industry trend, Competitive Intensity: Zoetis VETSCAN. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is IDXX a High Quality Earnings Stock?
Based on this 2024 filing, IDXX passes the first screen for high-quality earnings: the overall grade is B, and the earnings-quality score is 83/100. This is a research screen, not investment advice.
Read the report first
Understand IDEXX Laboratories, Inc. first, then decide if it belongs on your watchlist
The IDXX score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep IDXX with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the IDXX report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
The significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that the significance of gross margin in FY2024 is that gross margin of 61.0% reflects the disclosed CAG Diagnostics Recurring Revenue (consumables and reference lab services) mix.
Operating Margin is worth reading alongside the rest of the file because operating Margin is worth reading alongside the rest of the file because operating Margin is worth reading alongside the rest of the file because operating Margin is worth reading alongside the rest of the file because the 29.0% operating margin reflects the disclosed CAG Diagnostics Recurring Revenue economics — instrument installed base monetization through consumables.
On cf / net income, the useful point is that on cf / net income, the useful point is that on cf / net income, the useful point is that on cf / net income, the useful point is that OCF of $929M is 1.05x net income of $888M — high-quality earnings translation per the cash-flow reconciliation.
The reason FY2024 looks credible is that the accounting result and the cash result are moving together: $888M of net income came with $929M of operating cash flow and $808M of free cash flow. Catalyst In-Clinic Analyzer and ProCyte / SediVue give the filing a business explanation for why cash conversion stayed solid. The filing therefore looks like an operating story first and a financing story second: Catalyst In-Clinic Analyzer supports 29.0% operating margin, then cash conversion, then capital returns. There is enough cash support around Catalyst In-Clinic Analyzer that FY2024 does not need heroic accounting assumptions.
Moat Strength
In-Clinic Instrument Base is useful mainly because in-Clinic Instrument Base is useful mainly because in-Clinic Instrument Base is useful mainly because in-Clinic Instrument Base is useful mainly because sediVue per the product-line disclosures) creates a captive consumables-revenue base — the razor and blades economics.
Reference Lab Network matters because IDEXX's reference-lab network (sample pickup and results delivery to vet clinics) provides the breadth of test menu complement to in-clinic instruments as described in the lab-network footprint.
What switching cost really tells you is that what switching cost really tells you is that what switching cost really tells you is that what switching cost really tells you is that creating switching cost.
If you want the moat in plain language, start with Catalyst In-Clinic Analyzer and ProCyte / SediVue. In-Clinic Instrument Base and Vet Clinic Visit Volumes help explain why the company can defend pricing or wallet share without needing a monopoly narrative. What matters is that Catalyst In-Clinic Analyzer still delivered 55.7% ROE without sacrificing the cash profile or the operating position. That is the practical moat test: a competitor has to dislodge Catalyst In-Clinic Analyzer-driven behavior, not just underprice a SKU. The filing puts that point plainly: 'We have included certain terms and abbreviations used throughout this Annual Report on Form 10-K in the " Glossary of Terms and Selected Abbreviations'.
Capital Allocation
The allocation takeaway from free cash flow is that the allocation takeaway from free cash flow is that the allocation takeaway from free cash flow is that the allocation takeaway from free cash flow is that FCF of $808M (OCF $929M minus capex $121M) supports the disclosed share-repurchase program.
Share Repurchase is relevant because share Repurchase is relevant because share Repurchase is relevant because share Repurchase is relevant because IDEXX returns FCF principally through share repurchase as described in the buyback authorization.
On r&d reinvestment, the file suggests that on r&d reinvestment, the file suggests that on r&d reinvestment, the file suggests that on r&d reinvestment, the file suggests that on r&d reinvestment, the file suggests that on r&d reinvestment, the file suggests that on r&d reinvestment, the file suggests that IDEXX reinvests in next-generation diagnostic instruments and assays as described in the product-development pipeline.
The reason capital allocation matters here is simple: after paying to maintain Catalyst In-Clinic Analyzer and the rest of the platform, the business still threw off $808M of free cash flow. Capex is modest at 3.1% of revenue, so the real decision is how management redeploys the cash left over. Liquidity is workable at $288M, but the debt stack at $618M keeps the company tied to continued cash generation. The shareholder-return file is centered on repurchases rather than cash payouts, which makes execution discipline essential.
Key Risks
The risk significance of vet clinic visit volumes is that the risk significance of vet clinic visit volumes is that the risk significance of vet clinic visit volumes is that the risk significance of vet clinic visit volumes is that IDEXX's recurring-consumables revenue depends on vet clinic visit volumes as described in the industry-data trends (US pet visit volumes have been below pre-pandemic peaks).
Competitive Intensity belongs on the watch list because competitive Intensity belongs on the watch list because competitive Intensity belongs on the watch list because competitive Intensity belongs on the watch list because zoetis (via the VETSCAN imaging and diagnostics product line per public communications) and Antech / Mars Petcare-Group reference labs compete in vet diagnostics.
The point of pet insurance headwinds is that the point of pet insurance headwinds is that the point of pet insurance headwinds is that the point of pet insurance headwinds is that US pet owner spending discretion sensitivity (cost of living drag per public consumer-data) affects discretionary diagnostic-test ordering.
The filing makes the risk picture look cumulative because Vet Clinic Visit Volumes can amplify other pressures. The risk file matters because Vet Clinic Visit Volumes and other modest problems can still compound into a weaker cash outcome. The balance sheet is serviceable enough that the real risk remains operational, especially around Vet Clinic Visit Volumes. The real follow-up question is whether the present return profile survives the next change in demand or mix. A short line from the filing captures it: 'Our name, logo and the following terms used in this Annual Report on Form 10-K are either registered trademarks or trademarks of IDEXX Laboratories, Inc'.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.